Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection.
- Resource Type
- Academic Journal
- Authors
- Kurlander JE; 1Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA; 2VA Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan, USA; 3Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, Michigan, USA; 4Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, USA; 5UCLA Health Department of Medicine, Los Angeles, California, USA.; Barnes GD; Sukul D; Helminski D; Kokaly AN; Platt K; Gurm H; Saini SD
- Source
- Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 0421030 Publication Model: Print Cited Medium: Internet ISSN: 1572-0241 (Electronic) Linking ISSN: 00029270 NLM ISO Abbreviation: Am J Gastroenterol Subsets: MEDLINE
- Subject
- Language
- English
Introduction: Gastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use.
Methods: A methodological review of randomized trials comparing varying durations of DAPT after percutaneous coronary intervention.
Results: Among 21 trials, none incorporated protocol procedures or guidance for prescribing PPIs. Five reported rates of PPI use (range 25.6-69.1%).
Discussion: PPI gastroprotection is overlooked in major trials of DAPT. Appropriate use of PPI gastroprotection represents an important opportunity to improve patient safety.